Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVeRT: Nivolumab and DC Vaccines in Recurrent Brain Tumors
NCT02529072Phase 1Completed
- Sponsor
- Gary Archer (Duke University)
- Start
- Jan 2016
- Primary completion
- Sep 2017
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nivolumab and dendritic cells pulsed with cytomegalovirus pp65 RNA in malignant glioma (2 arms), sponsored by Gary Archer (Duke University). Primary endpoint: The Safety of Administering DC Vaccines With Nivolumab at 12 months. Started Jan 2016; status: completed.
02
Drugs
nivolumabdendritic cells pulsed with cytomegalovirus pp65 RNA
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT02529072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02529072.